Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials

UCLA's Jonsson Comprehensive Cancer Center

UCLA's Jonsson Comprehensive Cancer Center
JCCC: A Comprehensive Cancer Center
JCCC Member Directory
Calendar
Contact Us
Map and Directions to JCCC
Social Media
Connect via Mobile
Privacy Practices
 
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

John Glaspy, M.D., M.P.H.
John Glaspy, M.D., M.P.H.

Specialty:

Hematology/Oncology
Internal Medicine
Medical Oncology

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Professor, Department of Medicine, Hematology/Oncology
Physician, Department of Medicine, Hematology/Oncology
Estelle, Abe and Marjorie Sanders Endowed Chair in Cancer Research, JCCC
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

Santa Monica-UCLA Medical Center and Orthopaedic Hospital
Ronald Reagan UCLA Medical Center

Education:

Fellowship:
Hematology and Oncology, UCLA School of Medicine, 1982 - 1983
Residency:
Internal Medicine, UCLA School of Medicine, 1980 - 1982
Internship:
Internal Medicine, UCLA School of Medicine, 1979 - 1980
Medical Degree:
M.D., UCLA School of Medicine, 1979
Degree:
M.P.H., UCLA Fielding School of Public Health, 1979

Certification(s):

Medical Board Certification(s):
Hematology, American Board of Internal Medicine, 1986
Medical Oncology, American Board of Internal Medicine, 1985
Internal Medicine, American Board of Internal Medicine, 1982

Contact Information:

Phone:
(310) 794-4955 Appointments
(310) 267-5964 Administrative
(310) 794-4955 Office
Email:
jglaspy@mednet.ucla.edu

Practice Information:

Clinical Interest(s):
Breast Cancer
Gastrointestinal
General Hematology
General Oncology
Lymphoma
Melanoma
Sarcoma
Stem Cell Transplant Breast

Scientific Interest(s):

Dr. John Glaspy's research focuses on the use of bone marrow transplants and chemotherapy for breast cancer and melanomas. He is exploring the use of low-fat diet-based treatments as an alternative to unsuccessful chemotherapy and/or bone marrow transplants.

Selected Cancer-Related Publications:

Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007; 369(9572): 1502-4.

Hirsh V, Glaspy J, Mainwaring P, Manegold C, Ramlau R, Eid JE. Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy. Trials. 2007; 8: 8.

Straatsma BR, Nusinowitz S, Young TA, Gordon LK, Chun MW, Rosen C, Seja E, Economou JS, Glaspy JA, Bozon V, Gomez-Navarro J, Ribas A. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. Am J Ophthalmol. 2007; 143(6): 958-969.

Glaspy J. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia. Oncology (Williston Park). 2006; 20(8 Suppl 6): 29-32.

Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung P, Hong-Gonzalez J, Freedland SJ, Said J, Gui D, Seeram NP, Popoviciu LM, Bagga D, Heber D, Glaspy JA, Aronson WJ. Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res. 2006; 12(15): 4662-70.

In the News: